

References

1. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am J Ophthalmol* 1994;118:445–450.
2. Aetna Inc. Clinical policy bulletin (no. 0701): Vascular endothelial growth factor inhibitors for ocular neovascularization. [Internet]. In: *Medicare pharmacy clinical policy bulletins*. Hartford (CT): Aetna, Inc.; 2009.
3. Agardh E, Hultberg B, Agardh C. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. *Curr Eye Res*. 2000; **21**: 543–549.
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* 1994;331:1480-7.
5. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreal injections. *Retina* 2004;24:13–19.
6. Alder VA, Su EN, Yu DY, Cringle SJ, Yu PK. Diabetic retinopathy: early functional changes. *Clin Exp Pharmacol Physiol* 1997;**24**:785–788.

7. Arevalo JF, Wu L, Sanchez JG, et al.. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy. Program and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal Society; September 9;2006 –13,p213.
8. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. *Ophthalmology* 2007; 114:743-750.
9. Avery RL, Pieramici DJ, Castellarine AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Program and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal Society;September 9, 2006.;13,p139.
- 10.Badr GA, Tang J, Ismail-Beigi F, Kern TS. Diabetes downregulates GLUT1 expression in the retina and its microvessels but not in the cerebral cortex or its microvessels. *Diabetes* 2000; 49:1016–1021.
- 11.Bakri SJ, Snyder M, Pulido JS, et al. Pharmacokinetics of Intravitreal bevacizumab (Avastin). Program and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina

References

- Specialists and European Vitreoretinal Society; September 9, 2006; 13, p 77.
12. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. *Vasc Pharmacol* 2002;39:225–37.
13. Barron H: MedWatch Genentech. Important drug warning [letter]. Rockville, Maryland: US Food and Drug Administration. Available at: http://www.fda.gov/medwatch/SAFETY/2005/Avastin_dearhcp.
14. Beer PM, Wong S, Falk NS, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two human subjects. Program and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal Society; September 9; 2006.–13, p 77.
- 15.. Bhavsar A.R, Grillone L.R, McNamara T.R, Gow J.A, Hochberg A.M and Pearson R.K. Predicting Response of Vitreous Hemorrhage after Intravitreal Injection of Highly Purified Ovine Hyaluronidase (Vitrace) in Patients with Diabetes. *Invest Ophthalmol Vis Sci*. 2008;49:4219–4225.
16. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. *J Clin Invest*. 2003;111:1287-1295.*

17. Bhisitkul RB. Anticipation for enzymatic vitreolysis. *Br J Ophthalmol*. 2001;85:1–2.
18. Bonini-Filho M, Costa RA, Calucci D, Jorge R, Melo LA, Jr., Scott IU. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. *Am J Ophthalmol*. Jun 2009;147(6):1022–30,1030.
19. Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis- Evans J, Moriarty P *et al*. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. *Br J Ophthalmol* 1997; **81**: 228–233.
20. Caldwell RB, Bartoli M, Behzadian MA, *et al*. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. *Curr Drug Targets*. 2005;6:511–24.
21. Cai J and Boulton M. The pathogenesis of diabetic retinopathy. *Eye*. 2002; 16:242–260.
22. Ceriello A. Hyperglycaemia: the bridge between nonenzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. *Diabetes Nutr Metab* 1999;12: 42–46.

References

23. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. *Diabetes Metab Res Rev* 2000;16: 393–407.
24. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. *J Mol Biol* 1999;293:865– 81.
25. Chew EY. Major clinical trials of vitreoretinal diseases. In: Regillo CD, Brown GC, Flyn HW (ed). *Vitreoretinal disease, the essentials*. New York: Theme Medical Publishers Inc. 1999;11:667–77.
26. Chibber R, Molinatti PA, Kohner EM. Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration. *Cell Mol Biol* 1999; 45: 47–57.
27. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. *Retina*. 2009 Apr;29(4):516-22.
28. Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. *Am J Ophthalmol* 1997;124: 433–446.

29. Cunha-Vaz JG, Leite E, Sousa JC, de Abreu JR. Blood retinal barrier permeability and its relation to progression of retinopathy in patients with type 2 diabetes. A four year follow-up study. *Graefes Arch Clin Exp Ophthalmol* 1993;231:141–145.
30. Cunningham ET, Adamis AP, Altaweel M, et al, Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology*. 2005;112(10):1747-1757.
31. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis from a single bevacizumab (Avastin) injection. *Retina*. 2006;26:354–6.
32. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM: Endothelial dysfunction in diabetes. *Br J Pharmacol*. 2000;130:963 –974
33. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study report 2. *Arch Ophthalmol*. 1985;103(11):1644-1652.

References

- 34.Duh E, Aiello LP: Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. *Diabetes*.1999;48:1899 –1906.
- 35.Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. *Kidney Int* 2000; 58(Suppl 77):S3–S12.
- 36.El-Batarny A M. Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. *Clinical Ophthalmology* 2007;1:(2)149–155
- 37.Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. *Endocr Rev*. 1997;18:4 –25
- 38.Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov* 2004;3:391–400.
39. Ferrara N () Anti-angiogenic drugs to treat human disease: an interview with Napoleone Ferrara by Kristin H. Kain. *Dis Model Mech* 2009;2:324-325.
- 40.Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. *Diabetes Care* 2004;27:2540–2553.
- 41.Frank RN. Diabetic Retinopathy. *N Engl J Med*. 2004;350:48–58.

42. Garner A. Histopathology of diabetic retinopathy in man. *Eye* 1993; 7: 250–253.
43. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. *Invest Ophthalmol Vis Sci*. 2005;46:726–733.
44. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL *et al*. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. *Lab Invest* 1998; 78: 1017–1027.
45. Gonzales CR; The VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. *Retina*. 2005;25:815–827.
46. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med*. 2004;351:2805–2816.

References

47. Gurler B, Vural H, Yilmaz N, Oguz H, Satici A, Aksoy N. The role of oxidative stress in diabetic retinopathy. *Eye* 2000;14:730–735.
48. Hoffmann-La Roche Ltd. *Health Canada endorsed important safety info on Avastin (bevacizumab)*. [Internet]. Ottawa: Health Canada; 2008. [cited 2010 Jan 13]. Available from: http://www.hc-sc.gc.ca/dhp_mpps/alt_formats/hpfbdgpsa/pdf/medeff/avastin_4_hpc-cps_eng.pdf
49. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. *Proc Natl Acad Sci U S A*. 2002;99:11393-11398.
50. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. *Can J Ophthalmol* 2007;42:807–11.
51. Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. *Retina*. 2009 Sep;29(8):1134-40.
52. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological,

References

- ischemia-induced retinal neovascularization. *J Exp Med* 2003;198:483–9.
53. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A *et al.* Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. *Science* 1996; **272**: 728–731.
54. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. *Eye (Lond)*. 2009 Jan;23(1):108-11.
55. Itakura H, Kishi S, Kotajima N, *et al.* Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. *Ophthalmology*. 2004;111:1880–84.
56. Jager RD, Aiello LP, Patel SC, *et al.* Risks of intravitreal injection: a comprehensive review. *Retina* 2004 ;24:676–98.
57. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). *Retina*. 2006 Nov;26(9):1006-13.
58. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. *Acta Ophthalmol Scand* 2007;85:119–20.

References

59. Kevil CG, Payne DK, Mire E, Alexander JS. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. *J Biol Chem* 1998;273:15099–15103.
60. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. *Ophthalmology*. 1998;105(10):1801-1815.
61. Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR, UK Prospective Diabetes Study (UKPDS) Group. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). *Diabet Med*. 2001;18(3):178-184.
62. Kuppermann BD, Thomas EL, de Smet MD, et al. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreal injection of highly purified ovine hyaluronidase (Vitrace) for the management of vitreous hemorrhage. *Am J Ophthalmol*. 2005;140:573–584.
63. K. Weng Sehu, William R. Lee. Ophthalmic pathology: an illustrated guide for clinicians. 2005;12:230-252.

References

64. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science*. 1989;246:1306-1309.
65. Lindgren G, Sjodell L, Lindblom B. A prospective study of dense spontaneous vitreous hemorrhage. *Am J Ophthalmol*. 1995;119: 458–465.
66. Li W, Yanoff M, Liu X, Ye X. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. *Chin Med J (Engl)* 1997;110:659–663.
67. Lo WR, Kim SJ, Aaberg TM Sr., Bergstrom C, Srivastava SK, Yan J, et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). *Retina*. 2009 Jul;29(7):926-31.
68. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. *Retina* 2006;26:512–18.
69. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. *Ann Pharmacother* 2007;41:614–25.

References

- 70.[MDRSG] Macugen Diabetic Retinopathy Study Group: Changes in retinal neovascularization following Pegaptanib (Macugen) therapy in diabetic individuals. *Ophthalmology*. 2006;113:23–8.
- 71.Manzano RPA, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). *Retina*. 2006;26:257–61.
- 72.Mason JO III, Nixon PA & White MF: Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. *Am J Ophthalmol*. 2006;142:685–688.
- 73.Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. *Retina* 2006;26:270–4.
- 74.McCain J. Renewing the assault on mRNA. *Biotechnol Healthcare*. 2004;1:44-53.
- 75.Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, Altieri DC. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by surviving targeting. *Am J Pathol* 2001; 158:1757–1765.
- 76.Michelson IC. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. *Trans Ophthalmol Soc UK* 1948; 68:137–180.

References

77. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. *Ophthalmology* 2005;112:1035–1047.
78. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. *Acta Ophthalmol.* 2008 Sep;86(6):683-7.
79. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. *Eur J Ophthalmol.* 2009 Sep;19(5):848-52.
80. Moradian S, Ahmadi H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. *Graefes Arch Clin Exp Ophthalmol.* 2008 Dec ;246(12):1699-705.
81. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J *et al.* Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. *J Cell Physiol* 2001; 188: 253–263.
82. Murata T, Nakagawa K, Khalil A, *et al.* The relation between expression of vascular endothelial growth factor and breakdown of the

References

- blood-retinal barrier in diabetic rat retinas. *Lab Invest* 1996;74:819–825.
83. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S *et al*. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995; 28:103–117.
84. Oshima Y, Sakaguchi H, Gomi F & Tano Y: Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. *Am J Ophthalmol*. 2006;142:155–158.
85. Ozaki H, Seo MS, Ozaki K, *et al*. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. *Am J Pathol* 2000;156:697- 707.
86. Parravano M, Menchini F, Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. *Cochrane Database Syst Rev*. [Internet] 2009 Oct 7.
87. Pe'er J, Shweiki D, Itin A, *et al*. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. *Lab Invest* 1995;72:638–645.

References

- 88.Qi JH, Claesson-Welsh L. VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. *Exp Cell Res* 2001; 263: 173–182.
- 89.Robinson CJ, Stringer SE.The splice variants of vascular endothelial growth factor (VEGF) and their receptors. *J Cell Sci.* 2001;114:853-865.
- 90.ROCHE: AVASTIN PRODUCT INFORMATION-14 MARCH 2008.
- 91.Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmic Surg Lasers Imaging* 2005;36:270–271.
- 92.Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. *J Cell Physiol* 2003;195:241-8.
- 93.Saxena S, Jalali S, Meredith TA, Holekamp NM, Kumar D. Management of diabetic retinopathy. *Indian J Ophthalmol* 2000;48:321-30.

References

94. Schmucker C, Antes G, Lelgemann M () Position paper: the need for head-to-head studies comparing Avastin versus Lucentis. *Surv Ophthalmol* 2009; 54:705-707.
95. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). *Retina* 2006; 26:262-269.
96. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. *JAMA* 2002;288:2579-88.
97. Smiddy WE, Flynn HW. Vitrectomy in the management of diabetic retinopathy. *Surv Ophthalmol*. 1999;43(6):491-507.
98. Sone H, Deo BK, Kumagai AK. Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. *Invest Ophthalmol Vis Sci* 2000;41:1876–1884.
99. Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. *Diabetologia* 1997;40:726–730.
100. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. *Retina*. 2006;26:275–8.

101. Spraul CW, Grossniklaus HE. Vitreous Hemorrhage. *Surv Ophthalmol*.1997;42:3–39.
102. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. *Br J Ophthalmol* 2001;85: 746–753.
103. [DRSRG] The Diabetic Retinopathy Study Research Group. 1976. Preliminary reports on effects of photocoagulation therapy. *Am J Ophthalmol*, 81:383–96.
104. [DRSRG] The Diabetic Retinopathy Study Research Group.. Photocoagulation treatment of proliferative diabetic retinopathy: Clinical applications of diabetic retinopathy study (DRS) findings, DRS report Number 8. *Ophthalmology*. 1981;88:583–600.
105. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan C-C, Brock TA, Williamson JR: Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. *J Clin Invest*. 1997;99:2192 –2202.
106. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreal injection of vascular endothelial growth factor produces retinal ischemia and microangiopathy in an adult primate. *Ophthalmology*. 1996;103:1820–8.

References

107. Tolentino MJ, McLeod DS, Toamoto M, et al. Pathological features of vascular endothelial growth factor-induced retinopathy in nonhuman primate. *Am J Ophthalmol*. 2002;133:373–85.
108. US Food and Drug Administration. MedWatch. Barron H, Genentech. Important Drug Warning [letter]. http://www.fda.gov/medwatch/SAFETY/2005/Avastin_dearhcp.pdf (accessed 20 May 2006).
109. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. *JAMA* 2005;293:1509–13.
110. Viores S. A., A. I. Youssri, J. D. Luna, et al., “Upregulation of vascular endothelial growth factor in ischemic and nonischemic human and experimental retinal disease,” *Histology and Histopathology*. 1997;12:1,99–109.
111. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. *Am J Ophthalmol* 2005;139:476–481.
112. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE: Identification of polymorphisms within the vascular endothelial

References

- growth factor (VEGF) gene: correlation with variation in VEGF protein production. *Cytokine*. 2000;12:1232 –1235.
113. Williams B. Vascular permeability/vascular endothelial growth factors: a potential role in the pathogenesis and treatment of vascular diseases. *Vasc Med* 1996;1:251–258.
114. Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. *Prog Retinal Eye Res*. 2003;22:1–29.
115. Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, et al. Comparison of two doses intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. *Retina* 2008;28:212-219.
116. Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG: Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. *J Diabetes Complications*. 2003;17:1 –6.
117. Yeoh J, Williams C, Allen P, Buttery R, Chiu D, Clark B, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. *Clin Experiment Ophthalmol*. 2008 Jul;36(5):449-54.

References

118. Zhong H, Hanrahan C, van der Poel H, Simons JW. Hypoxia-inducible factor 1 alpha and 1 beta proteins share common signaling pathways in human prostate cancer cells. *Biochem Biophys Res Commun* 2001;284: 352–356.